Source: Kapitales ResearchHighlights:

• EU approval now appears significantly closer after CHMP's positive recommendation.
• Commercial launch could unlock immediate milestone payments and long-term royalty streams.
• Investors are watching whether Europe becomes Neuren's next major growth catalyst.

Neuren Nears Landmark EU Milestone for Rett Syndrome TreatmentShares of ASX-listed Neuren Pharmaceuticals (ASX: NEU) climbed more than 25% after the company announced a major regulatory breakthrough for its Rett syndrome treatment, DAYBU® (trofinetide). Europe's drug regulator has moved DAYBU® one step closer to market approval after the Committee for Medicinal Products for Human Use (CHMP) endorsed the treatment following a renewed assessment. The recommendation now advances to the European Commission, which will determine whether the medicine receives marketing authorisation in the coming months. Subject to European Commission approval, DAYBU® could become the first treatment authorised across the European Union for managing neurobehavioural symptoms in Rett syndrome patients aged five years and older. The authorisation would also extend to the wider European Economic Area, covering all EU countries together with Iceland, Liechtenstein and Norway.Financial Upside Extends Beyond Regulatory SuccessThe recommendation also carries meaningful commercial implications for Neuren. Under its licensing agreement with US-based partner Acadia Pharmaceuticals, the company is eligible to receive a US$35 million milestone payment following the first commercial sale of DAYBU® in Europe if regulatory approval is secured. Beyond that, the agreement includes potential sales milestone payments of up to US$170 million, alongside tiered royalties linked to European net sales.The market responded swiftly as investors reassessed the earnings potential from expanding beyond existing approved markets. DAYBU® is already approved in the United States, Canada and Israel, making Europe a significant opportunity to broaden its commercial footprint.Why the Decision Matters?Rett syndrome is a rare neurological disorder that affects thousands of families worldwide, yet treatment options remain extremely limited. A positive European Commission decision would introduce the region's first approved therapy for the disorder's neurobehavioural symptoms, addressing a significant unmet medical need while strengthening Neuren's position in the rare disease sector.The development also reinforces confidence in Neuren's broader neurological pipeline, which includes NNZ-2591, an investigational therapy being evaluated across multiple rare neurodevelopmental disorders. Continued progress across these programs could diversify the company's long-term revenue opportunities beyond DAYBU®.OutlookAttention now shifts to the European Commission, which is expected to review the CHMP recommendation before issuing its final decision in the coming months. While regulatory approval is not guaranteed, the positive opinion represents one of the final and most significant milestones before commercialisation.For investors, the story extends well beyond a single regulatory event. European approval could unlock new revenue streams through milestone payments, royalties and future sales while strengthening Neuren's standing in the global rare disease market. If the final decision is favourable, the company may be entering a new phase of international commercial expansion, making the next regulatory update one of the market's most closely watched healthcare catalysts.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au